Therapies under development
| Class . | Target . |
|---|---|
| Proteasome inhibitors | |
| Marizomib | Proteasome |
| Oprozomib | Proteasome |
| HDAC inhibitors | |
| Ricolinostat (ACY-1215) | HDAC6 |
| ACY-241 | HDAC6 |
| Monoclonal antibodies | |
| AMG224 | BCMA |
| GSK2857916 | BCMA |
| Isatuximab (SAR650984) | CD38 |
| MOR202 | CD38 |
| Indatuximab (BT-062) | CD138 |
| Nivolumab | PD1 |
| Pembrolizumab | PD1 |
| Atezolizumab | PD-L1 |
| Durvalumab (MEDI4736) | PD-L1 |
| Small molecule inhibitors and others | |
| AMG176 | MCL-1 |
| CPI-0610 | Bromodomain |
| Dinaciclib | Cyclin-dependent kinases |
| Melflufen | Alkylating agent |
| Selinexor | Exportin 1 |
| Vemurafenib | BRAF |
| Venetoclax | BCL2 |
| Class . | Target . |
|---|---|
| Proteasome inhibitors | |
| Marizomib | Proteasome |
| Oprozomib | Proteasome |
| HDAC inhibitors | |
| Ricolinostat (ACY-1215) | HDAC6 |
| ACY-241 | HDAC6 |
| Monoclonal antibodies | |
| AMG224 | BCMA |
| GSK2857916 | BCMA |
| Isatuximab (SAR650984) | CD38 |
| MOR202 | CD38 |
| Indatuximab (BT-062) | CD138 |
| Nivolumab | PD1 |
| Pembrolizumab | PD1 |
| Atezolizumab | PD-L1 |
| Durvalumab (MEDI4736) | PD-L1 |
| Small molecule inhibitors and others | |
| AMG176 | MCL-1 |
| CPI-0610 | Bromodomain |
| Dinaciclib | Cyclin-dependent kinases |
| Melflufen | Alkylating agent |
| Selinexor | Exportin 1 |
| Vemurafenib | BRAF |
| Venetoclax | BCL2 |